Prevention of cisplatin-induced hearing loss by extended release fluticasone propionate intracochlear implants

Autor: Federico Kalinec, Erik Pierstorff, Wan-Wan Yang, Yen-Jung Angel Chen, William H. Slattery, Shirley Cheung
Rok vydání: 2019
Předmět:
Anti-Inflammatory Agents
0302 clinical medicine
Hearing
Medicine
030223 otorhinolaryngology
Evoked Potentials
Auditory
Fluticasone
Drug Implants
Assistive Technology
Rehabilitation
Ear
General Medicine
Implantation
Cochlea
medicine.anatomical_structure
Anesthesia
medicine.symptom
Otoacoustic Emissions
medicine.drug
Hearing loss
Otoacoustic Emissions
Spontaneous
Guinea Pigs
Clinical Sciences
Bioengineering
Antineoplastic Agents
Article
Fluticasone propionate
Paediatrics and Reproductive Medicine
03 medical and health sciences
Ototoxicity
030225 pediatrics
Evoked Potentials
Auditory
Brain Stem
otorhinolaryngologic diseases
Animals
Corticosteroids
Hearing Loss
Cisplatin
Round window
business.industry
Prevention
Spontaneous
Auditory Threshold
medicine.disease
Scala Tympani
Otorhinolaryngology
Delayed-Action Preparations
Pediatrics
Perinatology and Child Health
Implant
business
Brain Stem
Zdroj: Int J Pediatr Otorhinolaryngol
Popis: Objective Cisplatin is a chemotherapeutic drug known to induce hearing loss. Although corticosteroids may help to mitigate the ototoxic side effects of cisplatin, there are complications associated with their systemic and prolonged use. The goal of this study is to test the efficacy of extended-release fluticasone propionate intracochlear implant particles to protect against cisplatin-induced hearing loss. Methods We used guinea pigs (n = 9) injected with cisplatin (IP, 12 mg/kg weight). Fluticasone particles were delivered to the cochlear scala tympani through the round window membrane into the right ears of the guinea pigs (left ears being used as a control) two weeks prior to cisplatin administration, and hearing function was evaluated by ABR and DPOAE before implantation, immediately before cisplatin administration, and 2 weeks after the challenge with cisplatin. Data was statistically evaluated using paired t-test analysis. Results No significant differences were observed in ABR threshold between control and implanted ears on day 14 (23.9 ± 2.3 dB vs. 25.6 ± 1.3 dB, P = 0.524), whereas the significant cisplatin-induced hearing loss in control animals (23.9 ± 2.3 dB at day 14 vs. 40.7 ± 2.5 dB at day 28, P ≤ 0.0001) was prevented in implanted animals (25.6 ± 1.3 dB at day 14 vs. 25.0 ± 3.1 at day 28, P ≥ 0.85). A similar, though not statistically significant, trend was observed in DPOAE responses in untreated ears (7.9 ± 5.8 dB at day14 vs. −0.5 ± 5.3 dB at day 28, P = 0.654) as compared to treatment (11.1 ± 3.4 dB at day 14 vs. 13.6 ± 4.8 dB at day 28, P = 0.733). Conclusion These results suggest that fluticasone intracochlear implants are safe and able to provide effective otoprotection against cisplatin-induced hearing loss in the guinea pig model.
Databáze: OpenAIRE
Externí odkaz: